“
TL;DR
The review found a limited number of studies and noted that while some candidate genes show changes, genome-wide findings lack reproducibility, highlighting DNA methylation's potential as a biomarker for obesity treatment.
Frontiers in Endocrinology · 4 authors, 3 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The review found a limited number of studies and noted that while some candidate genes show changes, genome-wide findings lack reproducibility, highlighting DNA methylation's potential as a biomarker for obesity treatment.
The review identified 19 relevant studies from the last five years: nine candidate gene-based and ten genome-wide approaches. The authors state that the analysis of DNA methylation in longitudinal designs is very recent and the number of studies is too low to draw definitive conclusions. While a number of candidate genes have been validated, genome-wide studies currently lack reproducibility. Limitations include the predominance of blood sample analysis over metabolic target tissues, the influence of the gut microbiome, and the need for larger, standardized studies. The review suggests DNA methylation has potential as a biomarker for improving obesity stratification and treatment.